Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03275103 · ClinicalTrials.gov registry record · Phase 1
Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
A Phase 1 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 355
- Enrollment target
NCT03275103: Completed Phase 1 study, sponsored by Genentech.
NCT03275103 is a Phase 1 study that has completed, run by Genentech. The registered enrollment target is 355 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (492% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03275103, a Phase 1 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 355 participants
- Enrollment target
Study Summary
This is a phase I, multicenter, open-label, dose-escalation study of cevostamab administered as a single agent by IV infusion to participants with relapsed or refractory multiple myeloma (R/R MM).
Primary Outcome
An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure.
Interventions
- DRUG Tocilizumab
- DRUG Cevostamab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 355 participants |
| Start Date | 2017-09-19 |
| Est. Completion | 2026-01-07 |
| Phase | Phase 1 |
What the finished NCT03275103 record still lists
NCT03275103 is an interventional study that assigns participants to a tested intervention. The registered 355 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (492% higher).
The record links to 0 conditions, and to 2 interventions - of which Tocilizumab is the first listed.
NCT03275103 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03275103 about?
NCT03275103 is a clinical study titled "Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)". This is a phase I, multicenter, open-label, dose-escalation study of cevostamab administered as a single agent by IV infusion to participants with relapsed or refractory multiple myeloma (R/R MM).
What is the current status of trial NCT03275103?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 355 participants. The study started on 2017-09-19. Estimated completion is 2026-01-07.
What interventions are being tested in trial NCT03275103?
The interventions under investigation include: Tocilizumab (DRUG), Cevostamab (DRUG).
Who is sponsoring clinical trial NCT03275103?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03275103's enrollment target sits among peer trials
355 95th of 2000 higher than 1,906 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07133308 · 355 participants · Phase 3
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
- NCT07193511 · 355 participants · Phase 1
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
- NCT06077838 · 356 participants · NA
RELAXaHEAD for Headache Patients (Phase III)
- NCT06293469 · 356 participants · NA
Accelerated Flap Coverage in Severe Lower Extremity Trauma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI